Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

Sweden · Healthcare · SEK

Key financials

ROE: -90.34%; 2025 (actual)
ROA: -36.41%; 2025 (actual)
Gross Margin: -
Net Margin: -
Total Assets: SEK 37,942.00K; 2025 (actual)
Net Income: -SEK 23,449.68K; 2025 (actual)
Valuation: SEK 78,730.53K; 2025 (actual)
Stock Price: SEK 2.59; 2025 (actual)

Historical & projected performance

Reported figures and Equlion model projections for the next 5 years.

Metric	2025 (actual)	2026	2027	2028	2029	2030
ROE	-90.34%	200%	66.67%	40%	28.57%	22.22%
ROA	-36.41%	-57.45%	-57.45%	-57.45%	-57.45%	-57.45%
Total Assets	SEK 37,942.00K	SEK 37,942.00K	SEK 37,942.00K	SEK 37,942.00K	SEK 37,942.00K	SEK 37,942.00K
Sector average	SEK 2,857,190.78K	SEK 2,900,240.60K	SEK 3,045,009.79K	SEK 3,280,286.42K	SEK 3,536,407.14K	SEK 3,762,908.71K
Net Income	-SEK 23,449.68K	-SEK 21,796.54K	-SEK 21,796.75K

Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.

Want the full financial forecast report for Newbury Pharmaceuticals AB (publ)? It covers the balance sheet, income statement and Equlion model projections.

Valuation	SEK 78,730.53K	SEK 73,180.23K	SEK 73,180.95K	SEK 73,181.33K	SEK 73,181.31K	SEK 73,181.28K
Sector average	SEK 3,960,502.41K	SEK 5,151,301.60K	SEK 5,189,236.02K	SEK 5,317,343.69K	SEK 5,514,329.75K	SEK 5,636,782.17K

Stock Price	SEK 2.59	SEK 2.41	SEK 2.41	SEK 2.41	SEK 2.41	SEK 2.41
Sector average	SEK 57.22	SEK 48.04	SEK 48.69	SEK 50.45	SEK 52.13	SEK 53.41